La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Incannex Healthcare Bilan de santé

Santé financière contrôle des critères 6/6

Incannex Healthcare possède un total de capitaux propres de A$84.1M et une dette totale de A$0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont A$88.6M et de A$4.5M.

Informations clés

Ratio d'endettement

AU$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	AU$33.36m
Fonds propres	AU$84.13m
Total du passif	AU$4.46m
Total des actifs	AU$88.59m

Mises à jour récentes de la santé financière

Incannex Healthcare (ASX:IHL) Is In A Good Position To Deliver On Growth Plans

Feb 14

Recent updates

Incannex Healthcare (ASX:IHL) Is In A Good Position To Deliver On Growth Plans

Feb 14

Incannex Healthcare (ASX:IHL) Has Rewarded Shareholders With An Exceptional 774% Total Return On Their Investment

Feb 28

How Is Incannex Healthcare's (ASX:IHL) CEO Compensated?

Dec 01

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de IHL ( A$34.7M ) dépassent ses passifs à court terme ( A$3.8M ).

Passif à long terme: Les actifs à court terme de IHL ( A$34.7M ) dépassent ses passifs à long terme ( A$616.1K ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: IHL est sans dette.

Réduire la dette: IHL n'a actuellement aucune dette, mais nous ne pouvons pas comparer avec il y a 5 ans car nous n'avons pas de données pour cette période.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: IHL dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: IHL dispose d'une marge de trésorerie suffisante pour 1.8 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 36.4 % chaque année.

Incannex Healthcare Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Incannex Healthcare Inc. SHS to Be Deleted from OTC Equity

Incannex Healthcare Limited Files Form 15

Incannex Healthcare (ASX:IHL) Is In A Good Position To Deliver On Growth Plans

Recent updates

Incannex Healthcare Inc. Receives Approval from the US Food and Drug Administration to Conduct its Investigational New Drug Opening Phase 2 Clinical Trial

Incannex Healthcare Inc. Completes Patient Dosing in 115 Participant Bioavailability/Bioequivalence Clinical Trial for Proprietary Sleep Apnea Drug Candidate IHL-42X

Incannex Healthcare Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Incannex Healthcare Inc. Announces Patient Dosing Commencement in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

Incannex Complete Successful Pre-Ind Meeting with the Fda for Cannquit-O for Treatment of Opioid Use Disorder

Incannex Healthcare Inc. Completes Successful Pre-IND Meeting with the FDA for CannQuit-N

Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis

Incannex Completes Dosing and Therapy in Phase 2 “Psigad” Clinical Trial Assessing Psilocybin-Assisted Psychotherapy for Generalized Anxiety Disorder

Incannex Healthcare Inc. Receives IRB Approval for the Reposa Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

Incannex Healthcare Ltd. Receives Ethics Board Endorsement for Psychedelic Assisted Therapy At Its First Clinic Based in Melbourne, Australia

Incannex Healthcare Inc Update on Ihl-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea

Incannex Healthcare Inc. SHS to Be Deleted from OTC Equity

Incannex Healthcare Limited Files Form 15

New minor risk - Financial data availability

Psychennex Pty Ltd Commences Preparations of an Investigational New Drug Application to the U.S. Food and Drug Administration

Incannex Healthcare Limited Receives Approval from the US Food and Drug Administration to Conduct Its Investigational New Drug Opening Pivotal IHL-42X Phase 2/3 Clinical Trial in the United States

New minor risk - Market cap size

Incannex Healthcare Limited Completes Positive Pre-IND Meeting with US FDA on IHL-675A for Treatment of Rheumatoid Arthritis

Incannex Submits IND Application to the US FDA for IHL-42X for Obstructive Sleep Apnoea

Incannex Healthcare Limited Receives HREC Approval Ph 2 Clinical Trial for IHL675

Incannex Receives Ethics Approval for Bioequivalence/Bioavailability Clinical Trial for IHL-42X, the Company’S Proprietary Drug for Treatment of Obstructive Sleep Apnoea

Incannex Healthcare Limited Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical Trial

Incannex Healthcare Limited Announces Independent Data Review Commences for PH 2 Trial Psilocybin

Incannex Healthcare Limited Expands Intellectual Property Position over IHL-42X

Incannex Healthcare Limited Announces Development Update for IHL-42X for Obstructive Sleep Apnoea

Less than half of directors are independent

Incannex Healthcare Limited Announces Positive Preliminary Data from Ihl-675A Ph 1 Trial

Incannex Healthcare Limited Completes Positive Pre-IND Meeting with US FDA on IHL-216A for Treatment of Concussion and Traumatic Brain Injury

Incannex Healthcare Limited, Annual General Meeting, Nov 29, 2022

Full year 2022 earnings released: AU$0.012 loss per share (vs AU$0.012 loss in FY 2021)

Less than half of directors are independent

Incannex Healthcare Limited Appoints Robert B. Clark to the Board of Directors

Incannex Healthcare Limited (ASX:IHL) completed the acquisition of APIRx Pharmaceuticals USA, LLC from its shareholders.

Incannex Healthcare Limited Engages Curia to Scale-up Manufacture of cGMP IHL-216A

Incannex Healthcare Limited Receives Ethics Approval to Commence Phase 1 Clinical Trial of Multi-Use Anti-Inflammatory Drug IHL-675A

Incannex Healthcare Limited Announces Board Changes

Less than half of directors are independent

Incannex Healthcare Limited Approves Election of George Anastassov as Director

Incannex Healthcare Limited Announces Positive Results from Phase 2 Clinical Trial Investigating the Effect of IHL-42X for Treatment of Obstructive Sleep Apnoea

Incannex Healthcare Limited Announces Positive Pre-IND Meeting with FDA for IHL-42X for Obstructive Sleep Apnoea

Incannex Healthcare Limited (ASX:IHL) completed the acquisition of APIRx Pharmaceuticals USA, LLC from its shareholders for $93.3 million on May 12, 2022.

Incannex Healthcare Limited Announces IHL-216A Was Observed to Have A Strong Neuroprotective Effect in A Widely Known Model of Sports Concussion

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Incannex Healthcare (ASX:IHL) Is In A Good Position To Deliver On Growth Plans

Incannex Healthcare Limited Completes Dosing Patients in Phase 2 Proof-Of-Concept Trial of IHL-42X for the Treatment of Obstructive Sleep Apnoea

Chairman of Medical Advisory Board exercised options to buy AU$7.1m worth of stock.

Independent Non-Executive Chairman exercised options to buy AU$2.5m worth of stock.

Chairman of Medical Advisory Board exercised options to buy AU$8.0m worth of stock.

First half 2021 earnings released: AU$0.003 loss per share (vs AU$0.003 loss in 1H 2020)

Incannex Healthcare Limited Files International Patent Application Entitled "Methods for the Treatment of Obstructive Sleep Apnoea" as Part of the IHL-42X Development Program

Company Secretary Glenn Fowles has left the company

Incannex Healthcare Limited Initiates Sixth Research Program Following More Positive in Vivo Results

Incannex Healthcare Limited Partners with Monash Trauma Group At the Department of Neuroscience to Conduct Study in Relation to Neuroprotective Capability of IHL-216A

Incannex Healthcare (ASX:IHL) Has Rewarded Shareholders With An Exceptional 774% Total Return On Their Investment

Incannex Healthcare Limited Initiates Fifth Research Program Following Further Positive in Vivo Results

New 90-day high: AU$0.22

New 90-day high: AU$0.21

Incannex Healthcare Limited Receives Positive Results from Another in Vivo (Animal) Study

Incannex Healthcare Limited, Annual General Meeting, Jan 25, 2021

Incannex Healthcare Limited Announces Positive Results from IH-216A TBI/Concussion Study

Incannex Healthcare Limited Receives Positive Results from Eurofins

How Is Incannex Healthcare's (ASX:IHL) CEO Compensated?

Incannex Healthcare Limited Receives Further Positive Results from Eurofins (Taiwan)

Incannex Healthcare Limited Receives Ethics Approval for Phase 2 OSA Trial

Incannex Healthcare Limited Appoints Paul Liknaitzky to Medical Advisory Board as Scientific Officer

Full year earnings released - AU$0.0058 loss per share

An unknown buyer acquired Gameday International Pty Ltd from Incannex Healthcare Limited (ASX:IHL) for $0.29 million.

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines